Pacira BioSciences, Inc. (NASDAQ:PCRX) specialty pharma firm, is reporting third quarter earnings results on Thursday 29th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.63 per share.
For the full year, analysts predict revenues of $ 428.02 million, while looking forward to income of $ 2.08 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 485.00 million ~ $ 500.00 million
Click Here For More Historical Outlooks Of Pacira BioSciences, Inc.
Previous Quarter Performance
Pacira BioSciences, Inc. recorded income for the second quarter of $ 0.12 per share, from the revenue of $ 75.50 million. The quarterly earnings decreased 70.73 percent while revenues declined 26.41 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.09 per share from $ 72.46 million in revenue. The bottom line results beat street analysts by $ 0.03 or 33.33 percent, at the same time, top line results outshined analysts by $ 3.04 million or 4.20 percent.
Stock Performance
Shares of Pacira BioSciences, Inc. traded low $ -0.63 or -1.20 percent on Wednesday, reaching $ 52.07 with volume of 479.90 thousand shares. Pacira BioSciences, Inc. has traded high as $ 52.43 and has cracked $ 50.73 on the downward trend
According to the previous trading day, closing price of $ 52.07, representing a 91.92 % increase from the 52 week low of $ 27.46 and a 18.22 % decrease over the 52 week high of $ 64.44.
The company has a market capital of $ 2.23 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Pacira BioSciences, Inc. will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.pacira.com
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
